Durolane (hyaluronic acid)
Introduction

- **Brand name:** Durolane
- **Generic name:** Hyaluronic acid
- **Pharmacological class:** Hyaluronan
- **Strength and Formulation:** 20mg/mL; viscoelastic gel for intra-articular injection
- **Manufacturer:** Bioventus
- **How supplied:** Single-use prefilled syringe (3mL)—1
- **Legal Classification:** Rx
Durolane
Indications

- Symptomatic treatment of mild-to-moderate knee or hip osteoarthritis
Dosage & Administration

- Remove joint effusion before inj
- Give as a single intra-articular inj
- **3mL per knee or hip**
- Local anesthetic by SC inj or topical freezing agents may be used prior to inj
- Use separate syringes for each joint
Considerations for Special Populations

- **Pediatric**: Not studied
- **Pregnancy**: Not studied
- **Nursing mothers**: Not studied
- **Geriatric**: No dosage adjustment required
Warnings/Precautions

- **Do not inject** by intravascular or extra-articular route, or in the synovial tissues or capsule
- **Avoid** infected or severely inflamed synovial joint, active skin disease or infection at or near inj site
- Venous or lymphatic stasis in the leg
Warnings/Precautions

- Pre-existing chondrocalcinosis
- Hyaluronic acid sensitivity
- **Avoid** strenuous activity within 48hrs after injection
Concomitant other intra-articular injectables: not established
Adverse Reactions

- Transient pain
- Swelling
- Joint stiffness
- Infection
Mechanism of Action

- The body’s hyaluronic acid constitutes a natural part of the synovial fluid and acts in the joints as a lubricant of cartilage and ligaments as well as a shock absorber.
- Injections of hyaluronic acid restores the viscosity and elasticity and can reduce the pain and improve joint mobility.
Clinical studies of Durolane for osteoarthritis of the knee and hip indicate significant mean benefit such as improvement in knee/hip pain and physical function at 6 months post-treatment vs baseline.

- Repeat treatment in the knee 6 months after initial injection did not give rise to an increased rate of adverse events.
Clinical Studies

- Controlled trials of Durolane in knee osteoarthritis showed significant benefits in responder rate vs **saline** and showed non-inferiority vs **methylprednisolone acetate** in a widely adopted effectiveness population of patients
Clinical Studies

- Treatment with Durolane also led to greater reduction in Visual Analog Scale (VAS) pain scores at 3 and 6 months vs Synvisc One (hylan G-F 20)

- For more clinical trial data, see full labeling
New Product Monograph

- For more information view the product monograph available at:

  http://www.empr.com/durolane/drug/34800/